Silence's business development strategy is based on its core values: Silence's intellectual property (including AtuRNAi®), its proprietary delivery systems (e.g. AtuPLEX®, DACC, and DBTC), and its internal programs. These three components position Silence as a leader in the field, able to bring the next generation of therapeutic on the patient's bed-side, alongside existing small molecules and antibodies therapies.
Silence has the know-how and the patented technology to help RNAi companies to develop specific and stable RNAi molecules. We are interested to discuss mutually beneficial agreements with any company interested to apply Silence's validated technology to develop a new drug in the RNAi Therapeutics field.
Silence would be happy to discuss with RNAi companies the use of its proprietary systems to deliver their cargo to: the vascular endothelium (with AtuPLEX®), the lung endothelium (with DACC), and the liver endothelium and hepatocytes (with DBTC). Silence also offers the potential for partners to use its impressive know-how and proprietary molecules (AtuFect) to help partners develop a delivery system for other organs.
Moreover, by combining its technology, intellectual property, know-how, and delivery systems, Silence can work with your company to develop breakthrough RNAi drug candidates against undruggable targets for which conventional approaches have failed. Silence owns the comprehensive platform and the know-how to take YOUR program from undruggable target to commercial success. So even if you are not in the RNAi field, come to discuss with us how Silence could develop with you the RNAi tools to go after this promising target you want to silence.
This is all backed-up by Atu027 our own internally developed oncology program. Silence has a very encouraging program, at the end of a phase I, against solid tumours. The efficacy demonstrated in multiple cancer animal models, the absence of drug-related side effects and the stabilisation of their diseases for 11 of the 27 patients treated in this phase I reinforced our willingness to advance this promising candidate. Silence would be interested to discuss with potential partners the possibility of joint development, or other types of agreement to move forward Atu027 for the treatment of some of the deadliest cancers with this new class of therapeutics.
